Begin main content

Reports

We found 5145 result(s)

Emerging Technology List — Device for Treatment of Ischemic Stroke

Published on: March 31, 2005
Result type: Reports
Product Line: Emerging Technology List

Tags

Brain Ischemia, Cerebrovascular Accident, Intracranial Thrombosis, Angiography, Angioplasty, Cerebral Revascularization, Stroke, Angioplasty, Balloon, Ischemic Attack, Transient, Stroke, Medical devices, Ischémie intracérébrale, Ischemic Attack, Transient, Ischemic stroke, Accident vasculaire cérébral, Thrombose intracrânienne, Blood clots, Angiographie, Balloon, Angioplastie, Merci Retriever, Corkscrew device, Revascularisation cérébrale

Minimally Invasive Hip Resurfacing

Published on: March 31, 2005
Result type: Reports

Metal-on-metal hip resurfacing is an emerging surgical alternative for younger patients who are expected to outlive a conventional total hip replacement implant. Minimally invasive hip resurfacing uses a smaller surgical incision and new techniques to expose the hip joint. Possible advantages include less damage to soft tissue, muscle and bon...

Tags

Arthroplasty, Hip Joint, Age Factors, Arthritis, Rheumatoid Arthritis, Osteoarthritis, Arthritis, Rheumatoid, Surgical Procedures, Minimally Invasive, Minimally Invasive Surgical Procedures, Hip Replacement Arthroplasty, Arthritis, Medical devices, Musculoskeletal, Arthroplastie, Surface arthroplasty, Articulation de la hanche, Hip resurfacing, Facteur âge, Surgical Procedures, Minimally Invasive, Chirurgie peu invasive, Minimally invasive hip resurfacing, Rheumatoid, Polyarthrite rhumatoïde, Arthrose

Pregabalin for Peripheral Neuropathic Pain

Published on: March 31, 2005
Result type: Reports

Pregabalin is an anticonvulsant drug that is under review for use in Canada. It was recently approved in the US and Europe for the treatment of adults with peripheral neuropathic pain (NeP). In most short-term randomized controlled trials (RCTs) of pregabalin in patients with diabetic peripheral neuropathy (DPN) and or post-herpetic neuralgia...

Tags

Anticonvulsants, Diabetic Neuropathies, Peripheral Nervous System Diseases, Neuralgia, Pain, DPN, Nervous system, Anticonvulsivants, Pregabalin, Neuropathies diabétiques, Diabetic peripheral neuropathy, Maladies du système nerveux périphérique, Névralgie, Post-herpetic neuralgia, Douleur

Emerging Technology List — Breath Test for Detection of Insulin Resistance (Diatest™)

Published on: March 30, 2005
Result type: Reports
Product Line: Emerging Technology List

Tags

Breath Tests, Spectrophotometry, Insulin Resistance, Diabetes Mellitus, Glucose Clamp Technique, Euglycemic Clamping, Diabetes Mellitus, Type 2, Spectrophotometry, Infrared, Diabète, Diabetes, Test hydrogène expiré, Diatest, Infrared, Spectrophotométrie, ISOMAX, Infrared analyzer, Insulinorésistance, Type 2, Type 2 diabetes, Technique clamp euglycémique hyperinsulinique, Hyperinsulinemic euglycemic clamp test

Emerging Technology List — Portable Home Hemodialysis

Published on: March 24, 2005
Result type: Reports
Product Line: Emerging Technology List

Tags

Renal Dialysis, Dialysis, Hemodialysis, Hemodialysis, Home, Kidney/urologic, Dialyse rénale, Home, Home Dialysis Plus, Personal Hemodialysis System, Insuffisance rénale

Economic evaluation of Glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention with stenting

Published on: March 11, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Name Glycoprotein IIb/IIIa inhibitor drugs (abciximab and eptifibatide) Disease or Condition Blood clots (thrombi) and atherosclerotic plaque can block the coronary artery supplying blood to the heart. Blockage may result in heart pain (angina) or acute coronary syndrome, including unstable angina and myocardial infarction. Percutaneo...

Tags

Cost-Benefit Analysis, Platelet Glycoprotein GPIIb-IIIa Complex, Myocardial Infarction, Platelet Aggregation Inhibitors, Thrombolytic Therapy, Unstable Angina, Treatment Outcome, Safety, Percutaneous Transluminal Coronary Angioplasty, Stents, Coronary Artery Disease, Angina, Unstable, Glycoproteins IIb-IIIa, Acute Coronary Syndrome, Heart attack, Angina, Crise cardiaque, Coronary artery disease, Medical devices, Analyse coût bénéfice, Economic evaluation, Complexe glycoprotéine IIb-IIIa membrane plaquettaire, Glycoprotein IIb/IIIa, Infarctus myocarde, Heart attacks, Inhibiteur agrégation plaquettaire, Glycoprotein IIb/IIIa antagonists, Abciximab, Eptifibatide, Glycoprotein inhibitor drugs, Traitement thrombolytique, Unstable, Angor, Évaluation resultants traitement, Clinical outcome, Sécurité Angioplasty, Transluminal, Percutaneous Coronary, Angioplastie, Percutaneous coronary intervention, Stent, Coronary stenting, Systèmes aide décision, Decision analytic modelling, évaluation économique, glycoprotéine IIb-IIIa, crises cardiaques, inhibiteurs des récepteurs de la glycoprotéine IIb-IIIa, abciximab, eptifibatide, inhibiteurs des GP IIb-IIIa, angine instable, résultat clinique, angioplastie coronaire transluminale percutanée, intervention coronaire percutanée, pose de stents, modélisation analytique décisionnelle

Memantine for treatment of moderate to severe Alzheimer's disease

Published on: March 11, 2005
Result type: Reports

Health Canada has issued a Notice of Compliance with conditions (NOC/c) for memantine in the treatment of moderate to severe Alzheimer's disease (AD). The evidence of relative benefit and harm from memantine in this population derives from two randomized controlled trials (RCT) of 24 to 28 weeks duration, in a total of 656 patients; and a pos...

Tags

Alzheimer Disease, Alzheimer's Disease, Memantine, Ebixa, Cholinesterase Inhibitors, Chemotherapy, Drug Therapy, NMDA, Alzheimer, Maladie d'Alzheimer, Anticholinestérasiques, Donepezil, Adjuvant, Adjunctive therapy, Chimiothérapie

Mycophenolate sodium (Myfortic)

Last Updated: March 3, 2005
Result type: Reports
Product Line: Common Drug Review
Generic Name: Mycophenolate sodium
Indications: Organ rejection in allogeneic renal transplants, Prophylaxis

  • Brand Name: Myfortic
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: S0034
  • Project Status: Complete
  • Submission Type: New

Economic evaluation of drug eluting stents

Published on: February 25, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Disease or Condition Patients with coronary artery disease commonly undergo balloon angioplasty to unblock narrowed arteries carrying blood to the heart. However, a frequent consequence of the treatment is re-narrowing (restenosis) of a blood vessel that has been opened. Technology Description Bare metal stents (BMS) were introduced in 1994 to r...

Tags

Angioplasty, Balloon Angioplasty, Stents, Drug Delivery Systems, Coronary Restenosis, Coronary Disease, Coronary Heart Disease, Cost-Benefit Analysis, Decision Support Techniques, Coronary Artery Disease, Angioplasty, Balloon, Coronary artery disease, Medical devices, Balloon, Angioplastie, Coronary stenting, Système délivrance médicament, Drug eluting stents, Restenose coronaire, Vaisseaux coronaires, maladies, Analyse coût bénéfice, ost effectiveness, Systèmes aide décision, Decision analytic model

Drug eluting stents: an economic evaluation

Published on: February 25, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Overviews

Technology Name Drug eluting stents Disease or Condition Patients with coronary artery disease commonly undergo balloon angioplasty to unblock narrowed arteries carrying blood to the heart. However, a frequent consequence of the treatment is re-narrowing (restenosis) of a blood vessel that has been opened. Technology Description Bare metal stent...

Tags

Angioplasty, Balloon Angioplasty, Stents, Drug Delivery Systems, Coronary Restenosis, Coronary Disease, Coronary Heart Disease, Cost-Benefit Analysis, Cost Effectiveness, Decision Support Techniques, Coronary Artery Disease, Angioplasty, Balloon, Coronary artery disease, Medical devices, Balloon, Angioplastie, Coronary stenting, Système délivrance médicament, Drug eluting stents, Restenose coronaire, Vaisseaux coronaires, maladies, Analyse coût bénéfice, Systèmes aide décision, Decision analytic model